- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
- Earnings
Novo Nordisk A/S Investor and Analyst Event at ADA Transcript
/- -
All right. I believe we're ready to roll. So welcome to the Novo Nordisk R&D event in conjunction with the ADA 2022 here in New Orleans in hot summer June. It's great to see all here, and we have a very nice R&D presentation coming up. And I have to remind you that this event is being broadcasted. And the setup is that we will do a presentation of some 40 minutes or something like that, followed by a Q&A. And then we have a small social event afterwards. So that's kind of the format.
And as usual then, I have to remind you around, especially when we talk about R&D, that there will be a number of forward-looking statements, and the future does not always pan out as we predict in our internal modeling and forecasting, so hereby warned appropriately.
So today, we are a team of 3 from management in Novo Nordisk. So starting with myself, Karsten Knudsen, CFO of Novo Nordisk for a little bit more than 4 years now. With me, I have Martin
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |